Primary biliary cirrhosis (PBC) is a chronic cholestatic disorder characterized by progressive, nonsuppurative inflammation and destruction of small bile ducts, and the presence of antimitochondrial antibodies (AMA) in the sera. PBC is considered to be associated with disturbances in both cellular and humoral immunity, but the etiology is still uncertain. Although PBC has been described in virtually all parts of the world, most of the epidemiologic data have been derived from Europe, and there are not so many reports from Asia.

In Japan symptomatic PBC was specified as one of "the intractable diseases" from 1990. Patients with symptomatic PBC who want to receive public financial aid from the Ministry of Health, Labour and Welfare must sign agreements and write applications. Then they are registered and can receive the public financial aid. The recognition of patients with symptomatic PBC is conducted by each prefecture. In 1999, the Ministry of Health, Labour and Welfare permitted the use of clinical data from the recognized patients with symptomatic PBC. Most prefectures, but not all, provided clinical data to the research committee of intractable hepatic diseases. Therefore, the data was also available to the research committee on the epidemiology of intractable diseases.
In the present study, we tried to elucidate the characteristics of patients with PBC in Japan by utilizing the clinical data when they applied to receive public financial aid, and compared the features of the patients in Japan with those in other countries.

In the fiscal year 1999, 9,761 prevalent cases with symptomatic PBC were registered. For our cross-sectional study we used the clinical data of 6,305 patients because not all prefectures provided the data, and chose the cases of 5,805 patients whose clinical data were written between 1999 and 2000; the data from residual cases were not written during the time, for example written in 1998 or before.

Patients whose conditions met one of the criteria below were diagnosed as having PBC following the previous reports in Japan.5-7

1. Chronic non-suppurative destructive cholangitis (CNSDC) is histologically observed and laboratory data do not contradict PBC.

2. AMA is positive. CNSDC is not histologically observed but histological findings are compatible with PBC.

3. Histological examination is not performed, but AMA is positive and clinical findings and course indicate PBC.

For the patients with symptomatic PBC, the following information was collected from the records: sex, date of birth, date of diagnosis, estimated onset time, symptoms and physical findings, complicated autoimmune diseases, laboratory data including serum levels of bilirubin, alkaline phosphatase (ALP), \( \gamma \)-glutamyl transpeptidase (\( \gamma \)-GTP), total cholesterol (T-chole), IgM, and AMA. We evaluated symptoms and physical findings, laboratory data, and complicated autoimmune diseases according to sex. We also examined the association of IgM levels with the positivity of AMA. In the present study, frequencies of items in the clinical data were analyzed, excluding "unclear" or blank spaces.

Statistical analysis was performed using SPSS* version 10.0 (SPSS Inc.). The chi-squared test was used for comparing the proportions of two groups, and the Mann-Whitney test was used to evaluate differences in clinical variables. P values less than 0.05 were considered to be statistically significant.

| Table 1. Demographic characteristics of the patients with primary biliary cirrhosis. |
|-------------------------------|-----------------|-----------------|-----------------|
|                               | both sexes      | males           | females         |
| No. of patients               | 5,805           | 646             | 5,159           |
| Age (year) mean ± standard deviation | 59 ± 10.7  | 60 ± 11.8  | 59 ± 10.5  |
| median                        | 60              | 62              | 59              |
| relative frequency (%)        |                 |                 |                 |
| <19 years                     | 0.1             | 0.6             | 0.1             |
| 20-29                         | 0.6             | 0.6             | 0.6             |
| 30-39                         | 2.8             | 3.3             | 2.8             |
| 40-49                         | 15.8            | 13.8            | 16.1            |
| 50-59                         | 30.4            | 24.1            | 31.1            |
| 60-69                         | 34.1            | 35.1            | 34.0            |
| 70-79                         | 14.3            | 19.7            | 13.7            |
| 80+                           | 1.7             | 2.8             | 1.6             |
| total                         | 100             | 100             | 100             |

| Table 2. Symptoms and physical findings of the patients with primary biliary cirrhosis (%). |
|---------------------------------------------|-----------------|-----------------|-----------------|
|                                             | both sexes      | males           | females         |
| Pruritus                                    | 53.3 (3,014/5,654) | 57.5 (358/623)  | 52.8 (2,656/5,031) | 0.03 |
| Jaundice                                    | 11.3 (648/5,717) | 15.4 (97/631)   | 10.8 (551/5,086) | <0.001 |
| Xanthomas                                   | 5.8 (310/5,339)  | 6.4 (38/595)    | 5.7 (272/4,744)  | 0.58  |
| Splenomegaly                                | 38.1 (2,100/5,508) | 37.8 (232/614) | 38.2 (1,868/4,894) | 0.89  |
| Esophageal varices                          | 19.1 (957/5,012) | 17.3 (95/550)   | 19.3 (862/4,462) | 0.27  |

*: Denominators are not equal because frequencies of items were analyzed, excluding "unclear" or blank spaces.
\*: Chi-squared tests for males vs. females.
Primary Biliary Cirrhosis in Japan

Table 1 presents the demographic characteristics of the patients. Of 5,805 patients, 646 (11%) were males, and 5,159 (89%) were females, therefore the male-to-female ratio was approximately 1:8.0, showing a much greater frequency in females. The mean and median ages of all patients were 59 and 60 years, respectively. The median age appeared to be somewhat higher in males (62 years) than in females (59 years). The highest frequencies were in the 60s for both sexes (35.1% for males and 34.0% for females, respectively). We tried to estimate the age at the onset of the disease from the records, and found that the median age was 52 years (55 years for males, 52 years for females, respectively).

Symptoms and physical findings
Pruritis was present in 53.3%, jaundice in 11.3%, xanthomas in 5.8%, splenomegaly in 38.1%, and esophageal varices in 19.1% of all patients (Table 2). Pruritus and jaundice were found significantly more frequently among males than among females.

Laboratory data
Key laboratory data are summarized in Table 3. Levels of total bilirubin, ALP, and γ-GTP were significantly higher among males than among females, whereas levels of T-Chole and IgM were significantly higher among females than among males. AMA was positive in 86.6% of all cases, and its positive rate was significantly higher among males than among females (90.9% for males, 86.1% for females, respectively). Table 4 shows a significant association of IgM levels with the positivity of AMA, i.e., a higher IgM level, and a higher rate of AMA-positive patients (P for trend <0.001).

Complicated autoimmune diseases
Complications such as Sjögren's syndrome, rheumatoid arthritis, chronic thyroiditis, and scleroderma including CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectases) were found in 13.5%, 7.3%, 4.4%, and 2.0% of patients, respectively (Table 5). All these complicated diseases were found significantly more frequently among females than among males.

The patients with PBC were characterized by a high proportion of females, especially of middle age. It has been reported that 90% to 95% of patients with PBC are females, with a median age at the time of diagnosis in the early 50s. In Japan, the Research Committee on the Epidemiology of Intractable Diseases conducted two rounds of nationwide surveys of PBC. These surveys reported that the male-to-female ratio was 1:8.3-9.1, and that for males the percentage of patients gradually increased from their 40s, reaching the highest frequency age group between 60 and 70

### Table 3. Laboratory findings of the patients with primary biliary cirrhosis.

| Test                  | Total | Males | Females |
|-----------------------|-------|-------|---------|
| Total bilirubin (mg/dL) | 0.7-2.1 | 0.6-2.2 | 0.8-2.1 |
| ALP (IU/L)             | 475-1,120 | 500-1,150 | 450-1,050 |
| γ-GTP (IU/L)           | 17-175 | 20-200 | 15-150 |
| Total cholesterol (mg/dL) | 60-200 | 70-200 | 50-180 |
| IgM (mg/dL)            | 150-500 | 150-500 | 100-300 |
| Antimitochondrial antibody (AMA) positive (%) | 90.9 (552/607) | 90.9 (552/607) | 86.1 (4,213/4,895) |
Sakauchi F, et al.

was lower (86.6% of total patients). This may be one of the reasons that Japanese patients with PBC have lower frequency of certain types of AMA (e.g. anti-PDC-E2) than Europeans.13 More precise laboratory examinations for various types of AMA might resolve this issue.

Lacerda et al. reported that IgM levels were higher in AMA-positive than AMA-negative patients.17 Our results also showed an association of a higher IgM level with a higher frequency of AMA-positive patients.

It is reported that Sjögren’s syndrome, rheumatoid arthritis, thyroid diseases, and scleroderma are found in 75%, 10% to 20%, up to 15%, and 10% to 15% of patients with PBC, respectively.8 Patients in the present study had lower frequencies of complicated autoimmune diseases than those in western countries. Other studies in Japan have also reported lower complications of these diseases,5,6,7 but the difference in frequency of complicated autoimmune diseases between Japanese and Western people has not been clearly explained. Polymorphism of the human leukocyte antigen (HLA) might be related to the difference in races.18,19 Our study found a higher frequency of complicated autoimmune diseases among females than among males. This fact also shows that gonadal steroids are likely to play important roles in modulating autoimmune diseases.

In conclusion, using established recorded data, we described the clinical and biochemical features of PBC in Japan. The male-to-female ratio, frequencies by age groups, symptoms and physical findings among patients with PBC were consistent with previous reports from the two nationwide surveys. Inoue et al. also reported that the male-to-female ratio was 1: 7.9, and the peak incidence was in the 50s.7

It is still uncertain why females are more susceptible to autoimmune diseases, including PBC, than males. However, a sex-linked genetic influence and hormonal effect for females is one possible explanation.13 Females are considered to have the higher absolute number of CD4+ lymphocytes than males, and it is suggested that cytokine secretion is enhanced in the presence of estrogen.14 Moreover, androgens have been found to suppress the activity of autoimmune disease such as systemic lupus erythematosus in animal experiments.15 Gonadal steroids are likely to play important roles in modulating autoimmune diseases.

Pruritus, jaundice, and xanthomas are usually found in 55%, 10%, and less than 10% of the patients with PBC, respectively.1,2 Our results for pruritus, jaundice and xanthomas were similar to theses values. The percentage of splenomegaly among patients with PBC is reported to be 15%,2 but in the present study splenomegaly was observed in more patients than previously reported. The recent progress of diagnostic imaging techniques such as ultrasonography and computed tomography may be one possible explanation for this. Frequencies of jaundice and biliary enzyme levels were higher among males than among females. Further studies are required to clarify the association between sex and jaundice and biliary enzymes levels.

In Western countries it has been reported that AMA in PBC occurs in 90% to 95% of patients,1,14 but the positivity of AMA was lower (86.6% of total patients). This may be one of the reasons that Japanese patients with PBC have lower frequency of certain types of AMA (e.g. anti-PDC-E2) than Europeans.13 More precise laboratory examinations for various types of AMA might resolve this issue.

Lacerda et al. reported that IgM levels were higher in AMA-positive than AMA-negative patients.17 Our results also showed an association of a higher IgM level with a higher frequency of AMA-positive patients.

It is reported that Sjögren’s syndrome, rheumatoid arthritis, thyroid diseases, and scleroderma are found in 75%, 10% to 20%, up to 15%, and 10% to 15% of patients with PBC, respectively.8 Patients in the present study had lower frequencies of complicated autoimmune diseases than those in western countries. Other studies in Japan have also reported lower complications of these diseases,5,6,7 but the difference in frequency of complicated autoimmune diseases between Japanese and Western people has not been clearly explained. Polymorphism of the human leukocyte antigen (HLA) might be related to the difference in races.18,19 Our study found a higher frequency of complicated autoimmune diseases among females than among males. This fact also shows that gonadal steroids are likely to play important roles in modulating autoimmune diseases.

In conclusion, using established recorded data, we described the clinical and biochemical features of PBC in Japan. The male-to-female ratio, frequencies by age groups, symptoms and physical findings among patients with PBC were consistent with previous reports in Japan and from other countries. However, positivity of AMA and the frequencies of associated autoimmune diseases were lower among patients in Japan than among those in western countries.

Table 4. Association between serum IgM level and positivity of antimitochondrial antibody (AMA) among patients with primary biliary cirrhosis.

| Immunoglobulin M (IgM: mg/dL) | -299 | 300-599 | 600-899 | 900+ |
|-------------------------------|------|---------|---------|------|
| AMA (+) | 2,430 (82.4) | 1,456 (90.2) | 540 (91.8) | 332 (96.8) |
| AMA (-) | 520 (17.6) | 158 (9.8) | 48 (8.2) | 11 (3.2) |

Percentages in parentheses
P for trend <0.001

Table 5. Percentages of patients with primary biliary cirrhosis complicated with selected autoimmune diseases (%).*

| Autoimmune Disease | both sexes | males | females | p value<sup>®</sup> |
|--------------------|------------|-------|---------|-------------------|
| Sjögren’s syndrome | 13.5 (683/5,041) | 4.5 (25/555) | 14.7 (658/4,486) | <0.001 |
| Rheumatoid arthritis | 7.3 (390/5,373) | 2.5 (15/596) | 7.9 (375/4,777) | <0.001 |
| Chronic thyroiditis | 4.4 (258/5,805) | 0.8 (5/646) | 4.9 (253/5,159) | <0.001 |
| Scleroderma | 2 (117/5,805) | 0.6 (4/646) | 2.2 (113/5,159) | 0.011 |

* : Denominators are not equal because frequencies of items were analyzed, excluding "unclear" or blank spaces.
<sup>®</sup> : Chi-squared tests for males vs. females.
Primary Biliary Cirrhosis in Japan

We would like to express our appreciation for the Research Committee of Intractable Hepatic Diseases and chairman Professor Inaba of the Research Committee on the Epidemiology of Intractable Diseases.

1. Lindor KD. Primary biliary cirrhosis. In: Feldman M, Scharschmidt BF, and Sleisenger MH, eds. Sleisenger and Fordtran's gastrointestinal and liver disease: pathology/diagnosis/management. 6th ed. Philadelphia: W. B. Saunders Company; 1998:1275-83.
2. Lindor KD, Dickson ER. Primary biliary cirrhosis. In: Schiff ER, Sorrel MF, and Maddrey WC, eds. Schiff's diseases of the liver, 8th ed. Philadelphia: Lippincott-Raven Publishers; 1999:679-92.
3. Kim WR, Lindor KD, Locke GR, Therneau TM, Homburger HA, Batts KP, et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000;119:1631-6.
4. Uibo R, Salupere V. The epidemiology of primary biliary cirrhosis: immunological problems. Hepato-Gastroenterology 1999;46:3048-52.
5. Nakano T, Inoue K, Hirohara J, Arita S, Higuchi K, Omata M, et al. Long-term prognosis of primary biliary cirrhosis (PBC) in Japan and analysis of factors of stage progression in asymptomatic PBC (a-PBC). Hepatology Research 2002;22:250-60.
6. Sasaki H, Inoue K, Higuchi K, Yasuyama T, Koyata H, Kuroki T, et al. Primary biliary cirrhosis in Japan: National survey by the subcommittee on autoimmune hepatitis. Gastroenterol Jpn 1985;20:476-85.
7. Inoue K, Hirohara J, Nakano T, Seki T, Sasaki H, Higuchi K, et al. Prediction of prognosis of primary biliary cirrhosis in Japan. Liver 1995;15:70-7.
8. Kaplan MM. Primary biliary cirrhosis. In: Schiff L, and Schiff ER, eds. Diseases of the liver. 7th ed. Philadelphia: J. B. Lippincott Company; 1993:377-410.
9. Sherlock S, Heathcote J. Primary biliary cirrhosis. In: Bircher J, Benhamou JP, McIntyre N, Rizotto M, and Rodés J, eds. Oxford textbook of clinical hepatology. 2nd ed. Oxford University Press; 1999:1089-98.
10. Sherlock S, Dooley J. Primary biliary cirrhosis. In: Diseases of the liver and biliary system. 11th ed. Blackwell Science; 2002:241-53.
11. Shibazaki S, Nagai M, Asou E, Nakamura Y, Yanagawa H, Kawamura T, et al. Survey of patients with intractable diseases analyses of patients receiving financial aid for treatment. Jpn J Public Health 1997;44:33-46. (in Japanese)
12. Fuchigami H, Nishina M, Shibazaki S, Nagai M, Kawamura T, Ohono Y. Nationwide survey of intractable disease patients. Analyses of patients receiving public financial aid for treatment in fiscal year 1997. Jpn J Public Health 2002;49:774-89. (in Japanese)
13. Mackay IR, Gershwin ME. Pathogenesis of primary biliary cirrhosis. In: Krawitt EL, Wiesner RH, and Nishioka M, eds. Autoimmune liver diseases, 2nd ed. Elsevier Science BV; 1998:49-69.
14. Whitacre CC. Sex differences in autoimmune disease. Nat Immunol 2001;2:777-80.